Sign In
28 Apr 2011 16:02
28 April 2011
Plethora Solutions Holdings PLC
("Plethora" or "the Company")
Director Shareholding
Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that pursuant to the Company's recent placing on 21 April 2011, the Directors of the Company have increased their shareholdings as set out in the table below.
Number of shares held prior to the Placing | Placing Shares | Number of Shares Held | Percentage Holding of Current Issued Share Capital | |
Bill Robinson | 1,000,000 | 133,333 | 1,133,333 | 1.72% |
Dr Mike Wyllie | 686,494 | 333,333 | 1,019,827 | 1.55% |
Richard Horsman | 100,000 | 533,333 | 633,333 | 0.96% |
Ronald Openshaw | 250,000 | 26,669 | 276,669 | 0.42% |
Contact details:
Plethora Solutions Ronald Openshaw
| Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) Antony Legge (Nomad) / Martin Lampshire (Broker)
| Tel : +44(0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce | Tel: +44(0) 20 7947 4350
|
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503 - Virgafem), interstitial cystitis (PSD597 - Urolieve) erectile dysfunction (PSD510) and premature ejaculation (PSD502).
Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions.
The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com.
Follow the stocks
